Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression

Liu, Yang; Ho, Roger; Mak, Anselm

doi:10.1016/j.jad.2011.08.003

Cited by 815 publications

(561 citation statements)

References 67 publications

Supporting

Mentioning

524

Contrasting

Unclassified

Order By: Relevance

“…Increased expression of innate immune mediators, including cytokines and acute phase reactants, chemokines and soluble receptor molecules are among the most replicated findings not only in peripheral blood but in the cerebrospinal fluid (CSF) or in postmortem brain samples of suicide victims 41 . For instance, some meta-analyses have documented higher peripheral levels of pro-inflammatory cytokines namely IL-6, IL-8, IL-1β, TNF-α, soluble IL-2 receptor (sIL-2R) and C-reactive protein (CRP) in individuals with MDD when compared to healthy controls 42,43 . Conversely, in longitudinal population studies, higher CRP levels have been demonstrated to predispose individuals in developing subsequent depressive symptoms, thus supporting that the notion that the activation of the immune system may contribute to the patho-etiology of depression 44 .…”

Section: Inflammatory Aberrations Associated With Depressionmentioning

confidence: 99%

Depression in cancer: The many biobehavioral pathways driving tumor progression

Bortolato

Hyphantis

Valpione

et al. 2017

Cancer Treatment Reviews

248

179

View full text Add to dashboard Cite

Major Depressive Disorder (MDD) is common among cancer patients, with prevalence rates up to four-times higher than the general population. Depression confers worse outcomes, including non-adherence to treatment and increased mortality in the oncology setting. Advances in the understanding of neurobiological underpinnings of depression have revealed shared biobehavioral mechanisms may contribute to cancer progression. Moreover, psychosocial stressors in cancer promote:(1) inflammation and oxidative/nitrosative stress; (2) a decreased immunosurveillance; and (3) a dysfunctional activation of the autonomic nervous system and of the hypothalamic-pituitary-adrenal axis. Consequently, the prompt recognition of depression among patients with cancer who may benefit of treatment strategies targeting depressive symptoms, cognitive dysfunction, fatigue and sleep disturbances, is a public health priority. Moreover, behavioral strategies aiming at reducing psychological distress and depressive symptoms, including addressing unhealthy diet and life-style choices, as well as physical inactivity and sleep dysfunction, may represent important strategies not only to treat depression, but also to improve wider cancer-related outcomes. Herein, we provide a comprehensive review of the intertwined biobehavioural pathways linking depression to cancer progression. In addition, the clinical implications of these findings are critically reviewed.

show abstract

Section: Inflammatory Aberrations Associated With Depressionmentioning

confidence: 99%

Depression in cancer: The many biobehavioral pathways driving tumor progression

Bortolato

Hyphantis

Valpione

et al. 2017

Cancer Treatment Reviews

248

179

View full text Add to dashboard Cite

show abstract

“…Populations obtained from inpatient and outpatient settings also had higher IL-6 levels compared to the general community (Hiles et al, 2012b). In a meta-analysis by Liu et al (2012), elevated blood levels of soluble interleukin-2 receptor (sIL-2R), TNF-α and IL-6 in patients with depression were demonstrated, although effect sizes were significantly influenced by the composition of the blood sample. Specifically, differences in sIL-2R and IL-6 were significant both in plasma and serum, whereas TNF-α was significantly different from healthy controls only when it was measured via serum.…”

Section: Accepted M Manuscriptmentioning

confidence: 99%

A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers

Lopresti

Maker

Hood

et al. 2014

Progress in Neuro-Psychopharmacology and Biological Psychiatry

302

180

View full text Add to dashboard Cite

Biomarkers are regularly used in medicine to provide objective indicators of normal biological processes, pathogenic processes or pharmacological responses to therapeutic interventions, and have proved invaluable in expanding our understanding and treatment of medical diseases. In the field of psychiatry, assessment and treatment has, however, primarily relied on patient interviews and questionnaires for diagnostic and treatment purposes. Biomarkers in psychiatry present a promising addition to advance the diagnosis, treatment and prevention of psychiatric diseases. This review provides a summary on the potential of peripheral biomarkers in major depression with a specific emphasis on those related to inflammatory/immune and oxidative stress/antioxidant defences. The complexities associated with biomarker assessment are reviewed specifically around their collection, analysis and interpretation. Focus is placed on the potential of peripheral biomarkers to aid diagnosis, predict treatment response, enhance treatment-matching, and prevent the onset or relapse of major depression.

show abstract

“…For instance, a recent meta-analysis collecting data from 29 individual studies reported that serum IL-2 receptor, IL-6 and tumor necrosis factor-a (TNF-a) levels are elevated in MDD patients (Liu et al, 2012;Najjar et al, 2013). Among these, IL-6 and TNF-a, correlate with exacerbation and normalization of depressive episodes and the risk of suicide attempts, and are therefore proposed to not only be trait but also state markers of the disorders (Janelidze et al, 2011).…”

Section: Purinergic Regulation Of Neuroinflammation In Cns Disordersmentioning

confidence: 99%

Purinergic mechanisms in neuroinflammation: An update from molecules to behavior

et al. 2016

View full text Add to dashboard Cite

a b s t r a c tThe principle functions of neuroinflammation are to limit tissue damage and promote tissue repair in response to pathogens or injury. While neuroinflammation has utility, pathophysiological inflammatory responses, to some extent, underlie almost all neuropathology. Understanding the mechanisms that control the three stages of inflammation (initiation, propagation and resolution) is therefore of critical importance for developing treatments for diseases of the central nervous system. The purinergic signaling system, involving adenosine, ATP and other purines, plus a host of P1 and P2 receptor subtypes, controls inflammatory responses in complex ways. Activation of the inflammasome, leading to release of pro-inflammatory cytokines, activation and migration of microglia and altered astroglial function are key regulators of the neuroinflammatory response. Here, we review the role of P1 and P2 receptors in mediating these processes and examine their contribution to disorders of the nervous system. Firstly, we give an overview of the concept of neuroinflammation. We then discuss the contribution of P2X, P2Y and P1 receptors to the underlying processes, including a discussion of cross-talk between these different pathways. Finally, we give an overview of the current understanding of purinergic contributions to neuroinflammation in the context of specific disorders of the central nervous system, with special emphasis on neuropsychiatric disorders, characterized by chronic low grade inflammation or maternal inflammation. An understanding of the important purinergic contribution to neuroinflammation underlying neuropathology is likely to be a necessary step towards the development of effective interventions.

show abstract

Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression

Cited by 815 publications

References 67 publications

Depression in cancer: The many biobehavioral pathways driving tumor progression

Depression in cancer: The many biobehavioral pathways driving tumor progression

A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers

Purinergic mechanisms in neuroinflammation: An update from molecules to behavior

Contact Info

Product

Resources

About